Pfizer (PFE) reported earnings of $0.64 per share in its second quarter, beating consensus forecast by 2 cents. The company reported revenue of $13.15 billion for the quarter, up 11% on a year-over-year basis. Revenue beat consensus forecast by $140 million. Lyrica sales for the quarter totaled $1.26 billion, up 3.4% on a year-over-year basis. Prevnar sales for the quarter were $1.26 billion, down 16.3% on a year-over-year basis. For 2016, PFE expects revenue to be between $51 billion and $53 billion. Non-GAAP earnings for 2016 are expected to be between $2.38 per share and $2.48 per share.